average weight loss with glp-1 agonists A big negative side effect from GLP-1's rapid may soon be a thing of the past. GLP-1s have left a big mark on health and wellness, but a big downside GLP-1 receptor agonists | How
Description
69 Evidence among individuals with CKD without T2DM remains scarce and no dedicated subgroup analyses from large obesity or cardiovascular outcome trials have reported BP effects in this population
Theres also cost and health insurance coverage to consider
Additionally, in July 2023, Sandoz expanded its portfolio with the launch of a new biosimilar GLP-1 medication, enhancing market access
Frederich R, Alexander JH, Fiodereck FT et al
Silverii, G
Therefore, rising geriatric population is expected to drive the GLP-1 receptor agonist market during the forecast period
